Is 6639.HK stock a buy after the intraday bounce?

6639.HK stock shows a tactical buy signal on volume-backed bounces. Meyka AI grades it B+ and projects HK$2.00. Treat entries as short-term trades and size positions for volatility. This is not financial advice.

What is Meyka AI's forecast for 6639.HK stock?

Meyka AI's forecast model projects **HK$2.00** for 6639.HK stock. That implies about **9.29%** upside from **HK$1.83**. Forecasts are model-based and not guarantees.

What key risks should holders of 6639.HK stock watch?

Watch interest coverage near **1.40**, debt/equity around **0.60**, and weak YTD performance. Regulatory moves and China dental demand can quickly change the outlook for 6639.HK stock.

What intraday plan fits the oversold bounce for 6639.HK stock?

Use a short-term plan: target **HK$2.00–HK$2.20**, stop near **HK$1.59**, and confirm with rising volume. Keep allocations small and use tight risk controls for 6639.HK stock.

HK Stocks

6639.HK Arrail Group (HKSE) +4.57% intraday 13 Mar 2026: Oversold bounce in play

ByDanny Kontos March 13, 2026

The 6639.HK stock is trading at HK$1.83 intraday on 13 Mar 2026, up 4.57% on heavy turnover. Volume of 8,867,500 shares is about 9.68x the average, signalling a classic oversold bounce as buyers re-enter. The intraday high is HK$1.92 and the low is HK$1.79, with the 50-day average at HK$1.84. We focus on why this spike may offer a short-term trading opportunity and how fundamentals and liquidity shape the risk-reward for Hong Kong healthcare investors.